Patent Application
20070025920
1. The Field of the Invention
The present invention relates to stable pharmaceutical solution formulations to be used with pressurized metered dose inhalers (MDIs) suitable for aerosol administration. In particular, the present invention relates to solutions to be used with pressurized metered dose inhalers (MDIs), which are suitable for aerosol administration containing the β2-agonist 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof (the hydrochloride salt is hereinafter referred to as TA 2005) and which is stable at room temperature for a pharmaceutically acceptable shelf-life.
2. The Relevant Technology
Pressurized metered dose inhalers are well known devices for administering pharmaceutical products to the respiratory tract by inhalation.
Drugs commonly delivered by inhalation include bronchodilators such as β2-agonists and anticholinergics, corticosteroids, anti-leukotrienes, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic efficacy and reducing side effects.
MDIs use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. Formulations for aerosol administration via MDIs can be solutions or suspensions. Solution formulations offer the advantage of being homogeneous with the active ingredient and excipients completely dissolved in the propellant vehicle or its mixture with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations so assuring more consistent uniform dosage administration.
For many years the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl3F (Freon 11 or CFC-11), CCl2F2 (Freon 12 or CFC-12), and CClF2-CClF2 (Freon 114 or CFC-114).
Recently, the chlorofluorocarbon (CFC) propellants such as Freon 11 and Freon 12 have been implicated in the destruction of the ozone layer and their production is being phased out.
Hydrofluoroalkanes ((HFAs) known also as hydro-fluoro-carbons (HFCs)) contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs.
HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed.
Due to the higher polarity of the HFA propellants, in particular of HFA 134a (dielectric constant D≧9.5), with respect to CFC vehicles (D≦2.3), HFA solution formulations may suffer to a greater extent of chemical stability problems with respect to the corresponding CFC formulations.
Preparation of stable HFA solution formulations is even more critical when bronchodilator β2-agonists belonging to the class of the phenylalkylamino derivatives are concerned; in particular, 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-methylethyl]amino]ethyl]-2(1H)-quinolinone suffers from chemical stability problems in this kind of vehicle and it is highly susceptible to chemical degradation.
Moreover, 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone is highly potent and its dosage-strength level is considerably less than many other drugs which can be administered by MDIs. Thus, its concentration in the aerosol formulation is very low and this factor, together with its chemico-physical properties, increases the difficulties in preparing a formulation which is stable and provides good dosage reproducibility when administered by MDIs.
In consideration of the problems outlined, it would be highly advantageous to provide formulations in the form of HFA solutions to be administered by MDIs aimed at providing pharmaceutical doses of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone and its therapeutic salts, in particular the hydrochloride salt (i.e. TA 2005), which do not require the use of refrigeration, remain chemically and physically stable during storage at ambient conditions of temperature and are characterized by adequate life time.
According to a preferred embodiment of the invention, formulations in the form of HFA solutions can be administered by MDIs to provide pharmaceutical doses of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or its salts into the lower respiratory tract of patients suffering from pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD), characterized by adequate shelf-life at room temperature.
These and other objects and features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
According to the present invention there is provided a pharmaceutical composition comprising as active ingredient 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof, in particular the hydrochloride salt, in a solution of a liquefied HFA propellant, a co-solvent selected from pharmaceutically acceptable alcohols and a specific amount of high concentrated (i.e. more than about 10 M, preferably more than about 12 M and in particular about 15 M) phosphoric acid. The apparent pH of said solution is comprised between 2.5 and 5.5.
The formulation is preferably a solution in which the active ingredient is completely dissolved.
The composition of the invention may be contained in a pressurized MDI having part or all of its internal metallic surfaces made of stainless steel, anodised aluminum or lined with an inert organic coating.
In fact, it has been found that, the chemical stability of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or its salts in HFA solution formulations can be dramatically improved by the use of high concentrated phosphoric acid in specific amounts as well as a proper selection of the kind of cans.
Moreover, it has been noticed that the stabilizing effect of phosphoric acid is not strictly correlated with its w/w percent amount in the formulation and when about 15 M phosphoric acid is used, it is present in a concentration interval from 0.0004 to 0.040% by weight on the total weight of the formulation, being 0.0008 w/w to 0.0075% w/w the preferred concentration interval.
The corresponding apparent pH interval is of 2.5-5.5, preferably 3.0-5.5, more preferably 3.5-5.0.
The attribution ‘apparent’ is used as pH is indeed characteristic of aqueous liquids where water is the dominant component (Mole Fraction>0.95). In relatively aprotic solvents, such as the HFA-ethanol vehicles used in these studies, protons are non-hydrated; their activity coefficients differ significantly from those in aqueous solution. Although the Nernst equation with respect to EMF applies and the pH-meter glass electrode system will generate a variable milli-volt output according to proton concentration and vehicle polarity, the “pH” meter reading is not a true pH value. The meter reading represents an apparent pH or acidity function (pH′).
It was previously noticed that when 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone.HCl [TA 2005] in a concentration of 4 μg/50 μl was titrated with a mineral acid and in particular with 0.08 M hydrochloric acid in a model vehicle system commercially available (HFA 43-10MEE, Vertrel XF, Dupont), according to a method developed by the applicant, the pH′ profile exhibited a shallow negative slope to about pH′=5.0; thereafter the acidity function dropped abruptly.
It was then found that in presence of lower concentrations of TA 2005 and for example with a concentration of 1 μg/50 μl (0.002% w/v) in presence of 0.08 M HCl, the pH interval is of 2.5-5.5 and the degree of stabilization is determined by the percent amount of the acid.
Further experiments have shown, and it will be described in detail in the following, that TA 2005 can be surprisingly better stabilized with high concentrated phosphoric acid, and in particular with about 15 M or 85% phosphoric acid.
In fact it has now been found that TA 2005 chemical degradation in a solution of a HFA propellant and a cosolvent not only depends on the acidity function of the solution, but it is also catalyzed by trace levels of metal ions and that TA 2005 stability can be enhanced by adding to the solution specific amounts of high concentrated phosphoric acid both to adjust the apparent pH in a well defined interval and to sequester metal ions.
Moreover, it has been observed that the use of inert containers, in particular having part or all of their internal metallic surfaces lined with an inert organic coating can enhance the chemical stability of the active ingredient in the HFA propellant solution.
According to a particular embodiment of the invention, there is provided a pressurized MDI for administering pharmaceutical doses consisting of a container lined with an inert coating, filled with a pharmaceutical composition comprising a solution of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone in HFA 134a as a propellant in turn containing from about 8 to about 15% w/w ethanol as a co-solvent, further containing from 0.0004% w/w to 0.0075% w/w of 85% (15.2 M) phosphoric acid.
The apparent pH of said solution is comprised between 3.0 and 5.5. The expression ‘% w/w’ means the weight percentage of the component with respect to the total weight of the composition.
The active ingredient in such a composition filled in said container has a good chemical stability and shelf-life at room temperature and meets the requirements of the ICH Guideline Q1A referring to “Stability Testing of new Active Substances (and Medicinal Products)”, wherein a significant change for a drug product is defined as a 5% change in assay from its initial value.
The pharmaceutical formulations of the invention may further contain further excipients and in particular a low volatility component in order to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
However, in a preferred embodiment the addition of other components to the formulation is avoided.
In WO 98/34596, the applicant described solution compositions for use in an aerosol inhaler, comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. Said application does not address the technical problem of the chemical stability of the active ingredient but it rather concerns the drug delivery to lungs.
In International Application No. PCT/EP99/09002 filed on Nov. 23, 1999 published on Jun. 2, 2000, as WO 00/30608 ('608), the applicant has disclosed pressurized MDIs for dispensing a solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterized in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminum or are lined with an inert organic coating. The '608 application makes no mention of a critical role of a mineral acid and in particular of phosphoric acid in order to improve the chemical stability of the active ingredient in the composition. On the contrary, it states that ipratropium bromide (one of the possible active ingredients) is stable in particular kinds of cans, with or without acids.
EP 673240 proposes the use of acids as stabilizers for preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs. Most examples relate to ipratropium bromide, an anticholinergic drug and only an example is presented for a β2-agonist, i.e., fenoterol. Although salbutamol is claimed, no exemplary formulations are provided. The stability data are reported only for ipratropium bromide and no difference is made between the use of organic and inorganic acids. Phosphoric acid is only cited among the possible inorganic acids. Furthermore, apart from ipratropium bromide, in EP 673240 no guidance is given with respect to the amount of acid which has to be added in order to stabilize the medicaments without compromising the stability of the whole composition in the can. The only hint can be found on page 5, lines 15 to 16, which says that an amount of inorganic acid should be added to obtain a pH value from 1 to 7, so a very broad and generic range.
WO 98/34596 refers to solution formulations containing a propellant and a physiologically acceptable polymer which could help the solubilization and the stability as well of the active ingredients.
WO 00/06121 refers to propellant mixtures for aerosol dinitrogen monoxide and a hydrofluoroalkane in the preparation of suspension and solution aerosols. The use of dinitrogen monoxide may improve the stability on storage of oxidation-sensitive active ingredients. As far as β2-agonists such as levosalbutamol sulfate, formoterol fumarate and salmeterol xinafoate, only examples referred to suspensions are reported.
In EP 1 157 689 ('689) of the applicant, stability data of a HFA 134a solution formulation containing 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) 3.5 μg/50 μl dose, 12% w/w ethanol, 1% w/w isopropyl myristate stabilised by different amounts of HCl 0.08M (1.0 and 1.4 μl) were reported (Example 7).
The formulations seemed to be provided with quite good stability if TA 2005 is present in a comparatively high concentration (e.g. 3.5 μg/50 μl) and if stored in upright position. Nevertheless, when the present inventors repeated the test with a rather low concentration of TA 2005 (e.g. 1 μg/63 μl), they noticed a progressive degradation of the active ingredient in the formulation; see Comparative Examples 1 and 3.
Moreover, the formulation exemplified in '689 contained isopropyl myristate as a low volatility compound in order to increase the MMAD (mass median aerodynamic diameter) of the delivered particles. It has been subsequently found that it would be highly advantageous to provide highly efficient TA 2005 formulations characterized by a deeper lung penetration by virtue of a significant fraction, of at least 30%, of fine particles, with a diameter equal or less than 1.1 μm. Therefore the low volatility compound should be avoided.
It has been subsequently also found that in this kind of highly efficient formulations, characterized by the presence of a fraction of particles equal to or less than 1.1 μm higher than 30% and even than 50% or more, TA 2005 can be present in a very low concentration, starting from 0.0005% w/v based on the total volume of the composition.
Said compositions have been described in another previous application of the applicant, WO 03/074025 ('025), wherein stability data of a HFA solution formulation comprising 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methyl amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) stabilized by HCl were reported.
The stability was determined on a formulation delivering 4 μg of active compound per actuation, stored upright at 5° C.: in said refrigerated conditions, after nine months, the TA 2005 assay was higher than 95%; see Comparative Example 2.
However, it has then been found by the present inventors that when present in lower concentrations and in other storage conditions, the active ingredient in the formulation rapidly degrades.
On the other hand, refrigeration is undesirable because many patients are required to carry the aerosol canisters on their persons.
According to the first aspect of the present invention, it has been found by the present inventors that, while according to the previous disclosure of '025 the preferred mineral acid was hydrochloric acid, the chemical stability of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone and its salts is enhanced by small amounts of high concentrated phoshoric acid (i.e. more than about 10M), preferably about 15M phosphoric acid, preferably comprised between 0.0008% and 0.01% w/w in the formulation. The mineral acid that better stabilizes the active ingredient 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone and its salts in the formulation is phosphoric acid, in particular higher concentrated phosphoric acid.
The aerosol formulations containing phosphoric acid are surprisingly stable at room temperature for a long life time.
According to a further aspect of the present invention there is provided a method of filling an aerosol inhaler with a composition of the invention, the method comprising: (a) preparing a solution of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or its salts in one or more co-solvents optionally containing a further active ingredient or excipient or an appropriate amount of a low volatility component; (b) filling the device with said solution; (c) adding a pre-determined amount of a phosphoric acid; (d) adding a propellant containing a hydrofluoroalkane (HFA); and (e) crimping with valves and gassing.
The active ingredient used in the aerosol compositions of the present invention is a long-acting β2-adrenergic agonist and its combinations with other active ingredients and in particular a corticosteroid or an antimuscarinic drug. Examples of a corticosteroid are: beclomethasone dipropionate, fluticasone propionate, butixocort, mometasone furoate, triamcinolone acetonide, budesonide and its 22R-epimer, ciclesonide and rofleponide. Examples of antimuscarinic are ipratropium bromide, oxitropium bromide and tiotropium bromide.
The active ingredient is 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-phenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof The preferred salt is the hydrochloride salt, sometimes referred to as TA 2005.
Although the preferred formulations of the invention are in the form of solutions, in case of the combinations, one of the two active ingredients could be present in suspension.
TA 2005 may be prepared as described in U.S. Pat. No. RE 33,024.
We prefer the formulation to be suitable for delivering a therapeutic amount of the active ingredient in one or two actuations. Preferably the formulation will be suitable for delivering 0.5-6 μg/dose, more preferably 1-4 μg/dose and in particular 1 to 2 μg/dose or 2 to 3 μg/dose, either alone or in combination. By “dose” we mean the amount of active ingredient delivered by a single actuation of the inhaler.
The formulations of the present invention will be preferably contained in cans having part or all of the internal surfaces lined with an inert organic coating. Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as polytetrafluoroethylene, fluorinated-ethylene-propylene, polyether sulfone and copolymers of fluorinated-ethylene-propylene polyether sulfone. Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
The most preferred coatings are perfluoroalkoxyalkane, perfluoroalkoxy-alkylene, perfluoroalkylenes such as polytetrafluoroethylene and fluorinated-ethylene-propylene and copolymers of fluorinated-ethylene-propylene polyether sulfones.
To further improve the stability, cans having a rolled-in rim and preferably a part or full rollover rim can be used.
The formulation is actuated by a metering valve capable of delivering a volume of between 50 μl and 100 μl.
Metering valves fitted with gaskets made of butyl rubber, in particular bromobutyl rubber of the kind described in WO 03/078538 are preferred in order to further improve the stability of the active ingredient in the formulation.
The hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof
The co-solvent is usually an alcohol, preferably ethanol.
The apparent pH range is advantageously comprised between 2.5 and 5.5, preferably between 3.0 and 5.5, even more preferably between 3.5 and 5.0. Rather concentrated, i.e. more than about 10 M, preferably more than about 12 M and most preferably about 15 M phosphoric acid is used to adjust the apparent pH. In the examples that follow 85% i.e. 15.2M phosphoric acid has been used.
The amount of acid to be added to reach the desired apparent pH will be pre-determined in the model vehicle reported before.
The active ingredient 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone or its salt is stabilized with rather concentrated, preferably about 15 M phosphoric acid. In particular, it is preferred to add phosphoric acid in an amount equivalent to 0.0004 to 0.040% w/w of 15M phosphoric acid, based on the total weight of the composition, preferably 0.0008 to 0.020% w/w of 15M phosphoric acid, based on the total weight of the composition, more preferably 0.001 to 0.010% w/w of 15M phosphoric acid, based on the total weight of the composition, still more preferably 0.002 to 0.0075% w/w of 15 M phosphoric acid, based on the total weight of the composition. For the purposes of the invention a still high concentrated phosphoric acid other than 15 M can be utilized. In this case, the person skilled in the art will be able to determine the right percent amount in view of the disclosure in the present application. In this embodiment it may also be preferred to avoid addition of other excipients or of the low-volatility component to increase the fraction of particles with a diameter less than or equal to 1.1 μm to at least 30% and to provide deeper lung penetration.
The 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone concentration will vary between 0.0005% and 0.024% w/v, based on the total volume of the composition, in order to deliver 0.5-6 μg per actuation, preferably between 0.001% and 0.016% w/v, based on the total volume of the composition, in order to deliver 1 to 4 μg per actuation, more preferably between 0.001% and 0.008% w/v, based on the total volume of the composition, in order to deliver 1 to 2 μg per actuation. For instance, for 1 and 2 μg/dose, wherein a 63 μl metering volume is used, the final concentrations of the hydrochloride salt TA 2005 delivered per actuation would be 0.0016% and 0.0032% w/v, respectively, based on the total volume of the composition. The amount of co-solvent in the composition is suitably 6 to 30% w/w, preferably 5 to 25% w/w, more preferably 5 to 20% w/w, even more preferably 8 to 15% w/w, based on the total weight of the composition.
In these conditions, the stability of TA 2005 is enhanced also at the very low dosage strengths of 0.5 or 1 μg per actuation.
The apparent pH values are preferably comprised between 3.0 and 5.0.
The stabilizing effects of phosphoric acid were also tested in a TA 2005 HFA formulation comprising as a further active ingredient budesonide, an anti-inflammatory 20-ketosteroid which meets with chemical stability problems when formulated in a HFA aerosol solution formulation.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof
In the following examples and comparative examples, and throughout this specification, all parts and percentages are by weight, and all temperatures are in degrees Celsius, unless expressly stated to be otherwise.
Comparative Example 1 corresponds to Example 7 of EP 1 157 689 and relates to the stability of acidified 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005)-HFA 134a solutions in cans coated with a fluorocarbon polymer.
A formulation of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) (3.5 μg/50 μl) was prepared by dissolving 0.84 mg of the active ingredient in HFA 134a containing 12% w/w ethanol and 1.0% w/w of isopropyl myristate. pMDI coated cans containing 1.0 and 1.4 μl of 0.08 M hydrochloric acid (corresponding respectively to an apparent pH of about 4.8 and 3.2) were set down on storage, upright at 50° C., and samples taken for analysis of TA 2005 contents at appropriate intervals.
Stability data obtained are given in Table 1. Each value is expressed as per cent nominal drug concentration.
The results indicate that formulations containing from 1.0 to 1.4 μl of 0.08 M HCl, whose apparent pH is comprised between 3.0 and 5.0, are stable for almost three months at 50° C. Table 1 below shows the stability data at 50° C. of the 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]quinolinone hydrochloride (TA 2005) formulations of Comparative Example 1
Comparative Example 2 corresponds to Example 1 of WO 03/074025 and shows a formulation for delivering a nominal dose of 1 μg of active ingredient per actuation that was prepared with the following formulation shown in Table 2.
*equivalent to 2.0 μl
The formulation (120 actuations/canister, overage of 30 actuations) was filled in aluminum canisters having the internal surface coated with Teflon and fitted with a metering valve having a 63 μl metering chamber. An actuator with an orifice diameter of 0.22 mm was used.
Analogous formulations able of delivering a nominal dose of 2, 3 or 4 μg per actuation of active ingredient were prepared. The 1 μg per dose formulation has been used only to determine the aerodynamic particle size distribution.
A stability study on a formulation able to deliver 4 μg per actuation was initiated storing the cans upright at 5° C.
Results were obtained as a mean of 2 cans.
After nine months the 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxy-phenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride assay was higher than 95% and therefore met with the requirements of the ICH guideline Q1A referring to “Stability Testing of new Active Substances (and Medicinal Products)”.
Two aluminum canisters having the internal surface coated with Teflon and fitted with commercial valves having a 63 μl metering chamber were filled with the following formulations shown in Table 3.
A stability study was carried out by storing the formulations in upright cans at 40° C. and 75% relative humidity. After three months of storage under these conditions the percent amount of TA 2005 was 73% and 77%, respectively.
According to the results of Comparative Examples 1 to 3, TA 2005 (8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride) can be stabilized by the use of hydrochloric acid if TA 2005 is present in the solution formulation in a comparatively high concentration (3.5 μg/50 μl; 4 μg/63 μl, respectively) and in refrigerated conditions. However, if it is present in a rather low concentration as desired for this kind of active ingredient (e.g. 1 μg or 2 μg/63 μl), it can no longer be stabilized by the use of hydrochloric acid. The active ingredient 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride is a very potent long acting [2-agonist active at a very low dosage-strength, which should be applied in a low concentration. Moreover, the storage in a refrigerator should be avoided.
As it will be demonstrated by the results of the following example, 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride can, however, be stabilized also in very low concentrations (e.g. 1 μg/63 μl) by the use of phosphoric acid in an amount equivalent to 0.0004 to 0.040% w/w, preferably 0.0008 to 0.020% w/w, more preferably 0.001 to 0.010% w/w, still more preferably 0.002 to 0.0075% w/w of 15.2 M phosphoric acid, based on the total weight of the composition.
An analogous formulation (see Table 4) for delivering a nominal dose of 1 μg of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) per actuation was prepared with the composition as follows, utilizing phosphoric acid as a stabilizer in place of hydrochloric acid.
Analogously, formulations capable of delivering a nominal dose of 0.5, 1.5, 2, 2.5, 3, 3.5 or 4 μg of active ingredient per actuation may also be prepared.
The formulation of Table 4 (120 actuations/canister, overage of 30 actuations) was filled in aluminum canisters having the internal surface coated with Teflon and fitted with commercial valves having a 63 μl metering chamber.
A stability study was carried out by storing the formulation in upright and inverted cans at 40° C. and 75% relative humidity. After six months of storage under these conditions the percent recovery of the active ingredient was very good with residual percent amount of TA 2005 up to 98% in the range of phosphoric acid of 0.001 to 0.0027% w/w.
Two compositions were tested containing TA 2005 and budesonide as active ingredients and two different concentrations of phosphoric acid.
Volume of the valve: 63 μl; strength: TA 2005 1 μg+budesonide 200 μg/actuation; no. of actuations: 120 (34 overfilling doses).
The two active ingredients in the compositions were stable after three months storage at 40° C. and 75% relative humidity, giving residual percent amounts of at least 95% TA 2005 and about 100% of Budesonide.
Therefore phosphoric acid is efficacious to stabilize TA 2005 also in the combination in the presence of budesonide and in presence of small quantities of water.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
| Number | Date | Country | Kind |
|---|---|---|---|
| EP04011424.1 | May 2004 | EP | regional |
This application is a continuation of International Application No. PCT/EP2005/002042, filed Feb. 25, 2005, which claims priority to U.S. Provisional Patent Application No. 60/547,798, field Feb. 27, 2004 and to European Application No. EP04011424.1, filed May 13, 2004, all of which are incorporated herein by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| 60547798 | Feb 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP05/02042 | Feb 2005 | US |
| Child | 11467515 | Aug 2006 | US |
